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Dual Genotype in Cutaneous T Cell Lymphoma: Immunoglobulin Gene 
Rearrangement in Clonal T Cell Malignancy 
To the Editor: 
In their study, Berger et al [l] reported a surprisingly high incidence 
of dual genotype in cutaneous T cell lymphomas (CTCL). Four of 
13 case; in ldikemic phase presented b&h a TCR and’ an IgJH 
rearrangement in the blood. 
We should like to raise a point about this interesting article by a 
comparison with our own results. Like Whittaker [2], we failed to 
find an additional JH rearrangement to TCR gene rearrangement in 
peripheral blood of Stzary syndrome, and we were surprised by the 
absence of any genotypic study in skin lesions. 
We studied 20 skin biopsies of CTCL with both JH and beta 
TCR gene probes. We also found a high incidence of bigenotype: 5 
cases (20%) had both a TCR and IgJH rearrangement. Thus, the 
skin samples confirmed the results obtained from the blood studies. 
But, unlike Berger, in one case we had more than a single JH allele 
rearranged. 
Berger et al presented three hypotheses for dual genotype in 
CTCL but our results suggest that there is a fourth explanation: The 
pathology may not be monoclonal but oligoclonal. It is well-known 
that, in some cases, there are more than two rearranged bands sug- 
gesting B cell biclonality [3] or different T cell clones in separate 
skin lesions from the same patient [4]. One of our cases agreed with 
the oligoclonality theory. Two skin biopsies from the same patient 
were studied; the second biopsy had, besides the same rearranged 
IgJH band, two additional rearranged bands, although they had the 
same genotype with beta and gamma TCR gene probes. 
We should be interested to know if the authors have eliminated 
this explanation for the cases in which they did not perform geno- 
typic study on T cell enrichment of peripheral blood lymphocytes. 
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REPLY 
We have read the letter by Drs. Bignon et al concerning our manu- 
script entitled “Dual genotype in cutaneous T cell lymphoma: Im- 
‘munoglobulin gene rearrangement in clonal T cell malignancy” by 
Berger et al (J Invest Dermatol90:73 - 77,1988). We would like to 
respond to the points raised in this letter. 
We did not study the skin lesions of these patients as the goal of 
our investigation was to confirm leukemic disease dissemination in 
already diagnosed patients by DNA hybridization and compare this 
technology with previously developed methods. We were inter- 
ested to learn that skin samples studied by Dr. Bignon and associates 
also contained a dual genotype. We are surprised that this phenome- 
non was not detected in the peripheral blood of these patients but we 
do not know the stage of their disease at the time of the study. It may 
be that these cells were sequestered in the skin at an early stage of 
disease progression and may enter the periphery at a later time point. 
Dr. Bignon and colleagues also suggest an oligoclonal origin for 
some cases of cutaneous T cell lymphoma (CTCL) based on the 
presence of additional JH rearrangements found in the skin biopsy 
of one patient. The presence of additional rearrangements detected 
with the JH probe could reflect clonal evolution involving the 
second allele, deletion of heavy-chain gene sequences, or other 
complex exchanges. It is equally possible that this JH rearrange- 
ment represents a dual neoplasm as the authors apparently did not 
confirm that these rearrangements were restricted to the clonal T 
cell population. Although some cases of CTCL may be oligoclonal 
in origin we have demonstrated no evidence to support this conten- 
tion in our studies and have confirmed monoclonality by karyotypic 
analysis in several cases. 
We believe further studies are required to fully elucidate the 
nature of the transformational event in CTCL and the origin of this 
disease. 
Carole L. Berger, Ph.D. 
Peter Benn, Ph.D. 
Arthur Eisenberg, Ph.D. 
Laurie Soper, Ph.D. 
Lisa Bennett, B.S. 
Barbara Cacciapaglia, B.S. 
Department of Dermatology, Columbia University, 
New York City, New York 
Lifecodes Corporation, Valhalla, New York 
